Jasper Therapeutics (NASDAQ:JSPR) Earns Neutral Rating from Cantor Fitzgerald

Cantor Fitzgerald reissued their neutral rating on shares of Jasper Therapeutics (NASDAQ:JSPR - Free Report) in a report published on Monday, MarketBeat reports.

Other equities research analysts also recently issued reports about the stock. HC Wainwright reissued a "buy" rating and issued a $40.00 price target on shares of Jasper Therapeutics in a report on Tuesday, March 11th. UBS Group cut their price objective on Jasper Therapeutics from $38.00 to $33.00 and set a "buy" rating on the stock in a report on Tuesday, May 13th. William Blair restated a "market perform" rating on shares of Jasper Therapeutics in a report on Monday. Finally, Oppenheimer cut their price objective on Jasper Therapeutics from $80.00 to $65.00 and set an "outperform" rating on the stock in a report on Thursday, May 15th. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $48.00.

Jasper Therapeutics Stock Performance

NASDAQ JSPR traded down $3.73 on Monday, reaching $3.04. The company's stock had a trading volume of 13,100,757 shares, compared to its average volume of 366,879. Jasper Therapeutics has a twelve month low of $1.68 and a twelve month high of $26.05. The stock has a market cap of $45.67 million, a PE ratio of -0.58 and a beta of 2.69. The firm's 50 day moving average is $5.32 and its two-hundred day moving average is $6.63.

Jasper Therapeutics (NASDAQ:JSPR - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The company reported ($1.41) earnings per share for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.24). Equities research analysts anticipate that Jasper Therapeutics will post -4.47 EPS for the current fiscal year.

Hedge Funds Weigh In On Jasper Therapeutics

A number of large investors have recently made changes to their positions in the business. Soleus Capital Management L.P. increased its holdings in shares of Jasper Therapeutics by 11.2% in the 4th quarter. Soleus Capital Management L.P. now owns 1,494,420 shares of the company's stock valued at $31,951,000 after purchasing an additional 150,755 shares during the period. Braidwell LP increased its holdings in shares of Jasper Therapeutics by 47.9% in the 4th quarter. Braidwell LP now owns 714,658 shares of the company's stock valued at $15,279,000 after purchasing an additional 231,358 shares during the period. T. Rowe Price Investment Management Inc. increased its holdings in shares of Jasper Therapeutics by 755.3% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 702,757 shares of the company's stock valued at $3,022,000 after purchasing an additional 620,592 shares during the period. Integral Health Asset Management LLC increased its holdings in shares of Jasper Therapeutics by 85.7% in the 4th quarter. Integral Health Asset Management LLC now owns 650,000 shares of the company's stock valued at $13,897,000 after purchasing an additional 300,000 shares during the period. Finally, Kingdon Capital Management L.L.C. increased its holdings in shares of Jasper Therapeutics by 9.6% in the 1st quarter. Kingdon Capital Management L.L.C. now owns 490,000 shares of the company's stock valued at $2,107,000 after purchasing an additional 43,000 shares during the period. Institutional investors and hedge funds own 79.85% of the company's stock.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.